Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
CCG-203971
Cat. No.:
OB0225LY-0036
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR and LC-MS.
Size:
Product Overview
Description:
CCG-203971 is an inhibitor of SRE activation that is used exclusively as a regulator for the inhibition of Zinc-finger proteins.
Synonym:
CCG203971; 1443437-74-8; N-(4-Chlorophenyl)-1-[3-(2-furanyl)benzoyl]-3-piperidinecarboxamide; N-(4-Chlorophenyl)-1-(3-(furan-2-yl)benzoyl)piperidine-3-carboxamide; 3-Piperidinecarboxamide, N-(4-chlorophenyl)-1-[3-(2-furanyl)benzoyl]-
CAS No.:
1443437-74-8
Compound CID:
71681561
Formula:
C23H21ClN2O3
Formula Weight:
408.88
Specification
Relative Density:
1.305 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
CCG-203971 can be used to explore gene regulatory mechanisms associated with tumorigenesis.
Library Information
Targets:
Rho; Ras
Pathways:
Cell cycle/Checkpoint; GPCR/G protein; MAPK; Rho/MRTF/SRF signaling
Plate Number:
AOCL-1
Plate Location:
d8
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
50 mg/mL; 122.29 mM
